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Background: Despite being a core business of medicine, end of life care (EoLC) is neglected. It is hampered by
research that is difficult to conduct with no common standards. We aimed to develop evidence-based guidance on
the best methods for the design and conduct of research on EoLC to further knowledge in the field.
Methods: The Methods Of Researching End of life Care (MORECare) project built on the Medical Research Council
guidance on the development and evaluation of complex circumstances. We conducted systematic literature
reviews, transparent expert consultations (TEC) involving consensus methods of nominal group and online voting,
and stakeholder workshops to identify challenges and best practice in EoLC research, including: participation
recruitment, ethics, attrition, integration of mixed methods, complex outcomes and economic evaluation. We
synthesised all findings to develop a guidance statement on the best methods to research EoLC.
Results: We integrated data from three systematic reviews and five TECs with 133 online responses. We
recommend research designs extending beyond randomised trials and encompassing mixed methods. Patients and
families value participation in research, and consumer or patient collaboration in developing studies can resolve
some ethical concerns. It is ethically desirable to offer patients and families the opportunity to participate in
research. Outcome measures should be short, responsive to change and ideally used for both clinical practice and
research. Attrition should be anticipated in studies and may affirm inclusion of the relevant population, but careful
reporting is necessitated using a new classification. Eventual implementation requires consideration at all stages of
the project.
Conclusions: The MORECare statement provides 36 best practice solutions for research evaluating services and
treatments in EoLC to improve study quality and set the standard for future research. The statement may be used
alongside existing statements and provides a first step in setting common, much needed standards for evaluative
research in EoLC. These are relevant to those undertaking research, trainee researchers, research funders, ethical
committees and editors.
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There are 57 million deaths each year. Despite being a
core business of medicine, end of life care (EoLC) is
neglected [1]. Although some people have excellent
EoLC, many do not die as they would wish [2]. A major
barrier is the lack of quality research; treatments, clinical
guidelines and services are limited by a lack of evidence
[3,4]. Surveys, qualitative studies and reviews recom-
mend that EoLC research is feasible and ethical [4] but,
funding of EoLC research is poor [1,5] and lacks com-
mon research guidance. Thus, randomised trials of EoLC
treatments and services remain rare, often limited by
poor recruitment, high attrition, bias, confounding and
small sample sizes [6-8]. There are challenges capturing
relevant outcomes in frail patients who may lack
capacity, raising ethical reservations [3,6,7,9,10]. Re-
search evaluating EoLC is characterised as too slow, too
expensive and frequently not producing useful results
[2]. There is a need to improve research methods to
evaluate models of service delivery and complex service
level interventions in EoLC and identify good research
practices to aid future studies. In response, the Methods
Of Researching End of Life Care (MORECare) collabor-
ation was established by the UK Medical Research Council
(MRC) and National Institutes of Health Research (NIHR)
to identify, appraise and synthesise ‘best practice’ methods
for research evaluating EoLC. This paper reports the totalFigure 1 Diagram showing components of MORECare and how these
Council; MORECare, Methods of Researching End of Life Care.integrated results from MORECare and the resulting guid-
ance statement.Methods
Design
The multiple problems of patients receiving EoLC mean
that treatments and interventions are complex, combining
symptom relief with physical, emotional, social and spiritual
care. We took as a starting point the MRC Guidance for
Developing and Evaluating Complex Interventions [11].
We planned a phased study (Figure 1). This involved
prioritising areas of uncertainty and difficulties in terms of
best research practice in EoLC and developing a statement
of best research practice to complement existing tools that
aid the conduct and reporting of research, such as the Con-
solidated Standards of Reporting Trials (CONSORT) for
randomised controlled trials (RCTs) [12] or Strengthening
the Reporting of Observational Studies (STROBE) for ob-
servational studies [13]. We conducted systematic literature
reviews, transparent expert consultations (TEC) involving
consensus methods of nominal group and online voting,
and stakeholder workshops to identify challenges and best
practice in EoLC research, including: participation recruit-
ment, ethics, attrition, integration of mixed methods, com-
plex outcomes and economic evaluation. We synthesised
all findings to develop the guidance statement.were integrated. EoLC, end of life care; MRC, Medical Research
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We defined EoLC as the total or holistic care of a person
during the last part of their life, from the point at which a
person’s health is in a progressive state of decline, usually
in the last year, the last months, weeks or days of life [14].
Interventions
EoLC includes both generalist and specialist services and
is offered across primary, secondary and tertiary care
settings [6]. EoLC offers integrated treatments and inter-
ventions including specific pharmacological or psycho-
logical therapies, education and clinical guidelines (for
example, care pathways), patient registers, and direct
multi-professional care [6,15].
Expert panel
We established a panel of experts in trials, quantitative,
qualitative and mixed method research, within and out-
side palliative care, patients/consumers, service providers,
clinicians, commissioners, national policy makers and
voluntary sector representatives (see Acknowledgements).
Phase I. Scoping and systematic reviews
We scoped the literature to prioritise areas for system-
atic literature reviews or consultation (Figure 1). We
searched six electronic data bases and reference lists for
either systematic reviews of EoLC services, or papers
recommending methods in EoLC research, as well as
papers recommending methods for the evaluation of
complex interventions. Three systematic literature re-
views were subsequently conducted, see Table 1 [16-18].
Phase II. Transparent Expert Consultation (TEC) and
Stakeholder Workshops
Five topics were selected for TEC based on results from
the scoping (a lack of empirical data) and expert opinion
(Figure 1). TEC is a rapid means to agree on recommen-
dations for action, using nominal group techniques toTable 1 Three systematic reviews conducted and integrated i
Review 1 To discover the experiences and views of participation in EoLC
identify best practices, we searched seven databases, hand sea
criteria were: original research papers on involvement in EoLC
was used to integrate evidence regarding patient, caregiver, p
in EoLC research, and identify best practices in research partici
Review 2 To appraise the state of the evidence of EoLC we conducted a
care teams in cancer. We searched six databases augmented b
is, with trained and dedicated professionals) palliative care in t
cancer and evaluation of the team. Outcomes were pain, symp
excluded if they did not test specialist palliative care services. M
Review 3 To appraise the methods used and challenges encountered in
the initial scoping into a systematic review specifically address
papers. Inclusion criteria were: systematic reviews on the effec
patients with advanced illness and/or their families. Narrative s
the main problems encountered and best practice solutions [1
EoLC, end of life care; MRC, Medical Research Council.generate recommendations and online ranking to ascer-
tain consensus (see Table 2) [19]. Each TEC followed the
same structure. In addition, we considered the conduct
and reporting of research in three further workshops -
two with patients/consumers and one with clinicians
and policy makers. Expert panel meetings were also held
every four months and considered randomisation and
alternative design approaches, the challenges for policy
makers and stakeholders, and the implementation of
research findings into practice.
Phase III. Synthesis
We planned from the outset to integrate the results
from all components to produce overall guidance on
‘best practice’ (Figure 1). We developed the MORECare
statement, based on the strongest recommendations
from all components of MORECare, as evolving good
practice guidance to design and conduct research. This
approach is similar to that for tools to support evaluative
research (for example, CONSORT, STROBE). Recom-
mendations which went beyond specific study designs
were collated for national/international groups.
Ethics
The research ethics committee of the University of
Manchester (reference number 10328) approved the
TEC component of MORECare. All TEC participants
gave written consent.
Results
The literature reviews and scoping together identified
15,695 papers, of these 62 were included in the three
systematic reviews [16-18]. The results of the scoping
and expert panel identified five main areas of conten-
tion/uncertainty that required TEC on: ethics [20],
statistics (managing missing data, attrition, and response
shift), [21] outcome measurement, [22] mixed method
research, [23] and health economics [24]. Attendees ofnto the final analysis
research of patients, caregivers, professionals and researchers and to
rched three journals and the bibliographies of relevant papers. Inclusion
research or its impact on participants. Critical interpretive synthesis (CIS)
rofessional and researcher views on, and experiences with, participation
pation [17].
systematic literature review of the evidence of effectiveness of palliative
y reference lists of earlier reviews. Inclusion criteria were: specialist (that
he home, hospital, or designated inpatient settings for patients with
toms, quality of life, use of hospital services and anxiety. Studies were
eta-synthesis combined the studies according to type of team [16].
developing and evaluating palliative and EoLC services we developed
ing this topic. We searched six databases and bibliographies of relevant
tiveness of generalist and/or specialist palliative care (SPC) services for
ynthesis appraised the methods used against the MRC guidance steps,
8].
Table 2 Transparent Expert Consultation (TEC) process
1. TEC planning by the MORECare project team, expert panel, and other experts identified in the literature to agree on the focus, scope the
literature, and identify topic experts with appropriate multiagency and discipline mix (from health care and clinical research, not only palliative
care) for the five workshops. We aimed always to include experts in the methods external to palliative and EoLC, researchers, clinicians, service
developers and policy makers in palliative care, patients and consumers.
2.. Specific research questions for each TEC were agreed by the expert panel and included in the invitations sent two to three months in advance
3. TEC conduct - format: Morning – initial consideration of issues through two or three brief presentations by experts on the subject followed by
equal time for discussion. Afternoon – three parallel working groups discussed and generated recommendations on ‘best practice’ to address the
issues. Each individual completed a standard form asking them to list specific best practice recommendations to overcome the issues and rank
these 1 to 5 (highest to lowest). Members of each group give feedback in turn on recommendations in priority order until the lists were
exhausted or time exceeded. Groups discussed recommendations and where possible agreed on the ranking of the importance of the proposals.
The afternoon was recorded to ensure that all aspects were captured and individual recommendation sheets and rankings were collated.
4. Editing of recommendations by the MORECare team to remove duplicates or merge similar proposals and remove any proposals which were
strongly generic rather than EoLC specific.
5. Online consultation on recommendations– inviting all TEC attendees and the MORECare Project Advisory Group, that included the expert panel,
to rank each proposal. Participants were asked to rate how much they agreed with each recommendation on a numerical scale from one
(strongly disagree) to nine (strongly agree). They were able to make comments on each recommendation and general comments at the end of
the consultation.
6. For each statement we report median agreement to determine the highest ranked items and interquartile (IQ) and total range to determine the
degree of consensus. Narrative comments were collated.
EoLC, end of life care; MORECare, methods of researching end of life care.
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online consultations (Table 3). The three stakeholder
workshops included 19 patients/carers and 12 clinicians.
The integrated top ranked recommendations and
synthesis with the literature formed: the MORECare
statement detailing 36 best practice solutions for
research in EoLC to improve study quality and set a
standard for research in the future (Table 4); and 13
national/international MORECare recommendations to
improve the environment for the development and
evaluation of interventions in EoLC (Table 5).
Study design recommendations
Three shortcomings for the MRC guidance [11] were
identified: (a) moving from feasibility and piloting to im-
plementation without robust evaluation; (b) failing toTable 3 Transparent Expert Consultation (TEC) considerations
TEC summit
topic
Areas considered in TEC workshops Number
attende
Ethics[20] (1) Participation in research; (2) Research ethics
committee approval; (3) Informed consent
28
Outcomes[22] (1) Outcome measure properties;
(2) Optimal time points; (3) Validity of proxy data
31
Mixed
methods[23]
(1) Phase I and pre-clinical studies; (2) Phase II
and III studies and trials; (3) Implementation
studies
33
Statistics[21] (1) Missing data; (2) Attrition; (3) Response shift 20
Health
economics[24]
(1) Cost methods and relevance to EoLC;
(2) Outcome assessment; (3) Equity issues.
28
TOTAL 140
EoLC, end of life care.develop the feasibility of the evaluation methods along-
side the feasibility of treatment/intervention; and (c) lack
of a theoretical framework underpinning treatment/
intervention. In EoLC this has resulted in a lack of prag-
matic trials, or, when attempted, trials that fail. There is
a need to build simultaneously the intervention and
research methods. Understanding the process of the
intervention and how it might work is important. Our
systematic reviews and expert panel discussions pro-
posed that considerations about implementation be inte-
grated into all phases of evaluation rather than only at
the end. This approach ensures that when the interven-
tion is ready to be rolled out, it is feasible with the con-
text and processes of implementation understood,
planned for and resourced. The MORECare statement
addresses these challenges, see Table 4 and Figure 2.and participants
of
es
Number of
online
responders
Backgrounds of individuals attending and
responding
26 ethicists, academics, researchers, members of
research ethics committees, clinicians, service
providers, commissioners, patients/carers
28 academics, researchers, clinicians, commissioners,
experts in outcome measurement
26 journal editors, academics, researchers, clinicians,
experts in health services research/mixed
methodology, patients/carers
19 statisticians, researchers, academics, clinicians,
patients/carers
34 health economists, service commissioners,
researchers, academics, clinicians, patients/carers
133
Table 4 MORECare Statement— checklist of components that require consideration when designing and conducting
EoLC intervention studies
Recommendations
Introduction/background 1. Present theoretical framework for the intervention and levels of need established
2. Present objectives appropriate to the level of intervention development
Study design 3. Indicate and justify stage in MRC guidance for development and evaluation of complex interventions, for
example, feasibility, preliminary evaluation, efficacy/cost effectiveness and wider effectiveness
4. Feasibility stages should test both feasibility of the intervention and of methods of evaluation, including outcome
measurement
5. Justify methods, considering appropriate use of existing data sets and secondary analysis as these may produce
rapid information
6. Justify methods of empirical studies considering mixed methods, observational studies and randomised trials
Study team 7. Ensure involvement from: (i) consumers, patients and caregivers; (ii) relevant clinicians; (iii) relevant
methodologists to develop study questions, questionnaires and procedures; and (iv) researchers familiar with the
challenges in EoLC studies
8. Ideally, involvement should be well established and continuing, beyond a specific study, with joint meetings or
rotations between clinical and research staff
Ethics 9. Note in ethics committee application MORECare recommendations that it is ethically desirable for patients and
families in EoLC to be offered involvement in research and MORECare evidence of patient willingness to be
approached
10. Work within legal frameworks on mental capacity, consent and so on, to ensure that those who may benefit
from interventions are offered an opportunity to participate if they wish
11. Collaborate with patients and caregivers in the design of the study, vocabulary used in explaining the study,
consent procedures and any ethical aspects
12. Attend the ethics committee meeting with a caregiver or patient, as a means to help the committee better
understand the patient perspective
13. Ensure proportionality in patient and caregiver information sheets, appropriate to the study design and level of
risk, as excessive information in itself can be tiring/distressing for very ill individuals
Participants 14. Adjust eligibility criteria to recruit those patients who may benefit most from intervention, ensuring equipoise
Procedures 15. Minimise burden for existing clinical staff for participation in the study
16. Clearly distinguish between service received and research activity interviews in study arms when multiple
interviews with patients are undertaken in trials, for example, using a graphical system [25]
Outcome measures 17. Choose outcome measures that meet the following criteria:
• established validity and reliability in relevant population
• responsive to change over time
• capture clinically important data
• easy to administer and interpret (for example, short and with low level of complexity)
• applicable across care settings to capture change in outcomes by location (for example, patients’ home,
hospital, hospice)
• able to be integrated into clinical care
• minimise problems of response shift (see below)
18. Consider including patients’ experience of care, as this is central to many interventions
19. Select time points of outcome measurement to balance the value of early recording, to reduce attrition, but to
allow enough time for the intervention to have had an effect
20. Consider the potential effect of response shift (that is, a change in a person’s internal conceptualisation or
calibration of the aspects measured). Questionnaires that include anchor points or descriptions of each response
category may be less problematic in this regard
Missing data and attrition
considerations
21. Estimate in advance levels of, and reasons for, attrition and missing data, integrating these into sample size
estimates and planned collection of data from proxies
22. Monitor during the study and report all levels of, and reasons for, attrition and other missing data
23. Assume missing quantitative data NOT to be at random unless proven otherwise
24. Test results from different methods of imputation – noting that ‘using only complete cases’ is a form of
imputation
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Table 4 MORECare Statement— checklist of components that require consideration when designing and conducting
EoLC intervention studies (Continued)
25. Use the MORECARE classification of attrition to describe causes of attrition: that is,
• ADD – attrition due to death;
• ADI - attrition due to illness;
• AaR - attrition at random.
26. Consider reasons for missing data which are not due to attrition, for example missed questionnaire, or missed
data item in questionnaire. Consider these in analysis and the potential imputations
Mixed method studies 27. Mixed methods can be appropriate in all phases of development and evaluation
28. Ensure appropriate multi-disciplinary skills mix or training of team
29. Define the theoretical paradigm and method of integrating results and safeguards to ensure rigour at the outset
30. Plan investigation to avoid undue burden of qualitative and quantitative questionnaires – perhaps dividing data
collection or selecting questions and/or sampling appropriately
31. Take into account any potential therapeutic effect of qualitative interviews where participants can express their
feelings, if these are similar to components of the intervention
32. Ensure that those collecting data are appropriately trained in qualitative data collection
Implementation 33. Consider implementation implications, including workforce and training needs, in all phases of the study
Cost-effectiveness 34. Integrate into preliminary evaluations and test feasibility of methods
35. Collect data on use of services including health, voluntary, social and informal care, to take societal approach to
care costs
36. Justify appropriate outcome measures to generate cost effectiveness
Note: This checklist should be used alongside other checklists depending upon the specific study design, for example, STROBE, CONSORT. EoLC, end of life care;
MORECare, methods of researching end of life care; MRC, Medical Research Council.
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Patient/caregiver participation
The evidence from the systematic reviews of quantitative
and qualitative studies and from the MORECare consul-
tations found that patients (even those close to death)
and families were consistently willing to engage in re-
search [17]. Factors reducing such willingness were
mainly physical (symptoms, frailty), cognitive impair-
ment or lack of mental capacity. Participating in re-
search was a positive experience for most patients and
carers. A minority experienced distress related to the
characteristics of the participants, research design (face
to face interviews and studies with a clear relevance to
care were preferred), or the way it was conducted (very
long information sheets, physically struggling to sign a
consent form, and poor accommodation of fluctuating
symptoms increasing distress). Sometimes the distress,
mostly about discussing difficult issues, was acceptable
and managed [17].
Ethics
Despite the problems of research among individuals who
are frail and may sometimes lack cognitive capacity,
there was unanimous support across all components of
MORECare that it is ethically desirable to offer patients
and families the opportunity to be involved in research
[20]. Concerns were expressed about an over-protective
culture, which sometimes denies patients and families
the choice to be involved in research. It can be unethicalto assume that patients should not be offered the oppor-
tunity purely because they have an advanced disease. In-
clusion and exclusion criteria may need to be broadened
to allow participation, taking into account any effects on
design (Table 4). Methods should take account of
expected potential loss of mental capacity. Ethical review
and especially governance arrangements were sometimes
inappropriate hindrances. Proposals are made for regula-
tory and legal change to address these (Table 5).
Clinician participation
Clinicians are often the first point of contact for EoLC
research. There are two aspects: their own willingness to
participate and the role they play in aiding the recruit-
ment of patients and/or families. There were mixed re-
ports about health professionals’ attitudes to EoLC
research across systematic literature reviews and TECs.
Problems can result in poor recruitment due to overt or
subconscious control of the recruitment for, or the con-
duct of, research (sometimes called gatekeeping), which
may be influenced by the attitudes towards, and priori-
tisation of, a research project or research as a whole.
Outcome measures and QALYs
Just as treatments in palliative and EoLC are complex,
so are outcomes. There is a need to capture changes in
symptoms and physical, emotional, social or spiritual
needs, at a time when a patient’s condition is deteriorat-
ing or death approaches. The measures required will
Figure 2 Key steps in developing and evaluating EoLC interventions. Although it is possible to begin at any step in the ladder it is
important to progress development with successful interventions. EoCL, end of life care.
Table 5 National/international MORECare recommendations to improve the environment for development and
evaluation of interventions in EoLC
Recommendations
Ethics 1. Create a Research Ethics Network for Palliative and End of Life care to further and disseminate best practice.
2. Train those working on ethics and research governance committees in the specific issues and wishes of patients in
palliative and EoL care and their families.
3. Seek to amend the law regarding consent so that advance consent for studies other than clinical trials of medicinal
products is legally effective. This would permit research among people who might develop problems with mental
capacity later.
Clinician/researcher
collaboration
4. Increase collaboration and understanding between clinicians and researchers in EoLC through rotations, joint
departments and exchanges
5. EoLC organisations to create a research-aware culture for practitioners by informing practitioners and patients on
admission to a service that the organisation is actively involved in research
6. Develop specific training for practitioners in palliative and end of life care about research practice, its value and how
to recruit
7. Introduce screening questions about patient/family willingness to be approached for research (as a general principle)
in routine initial assessments on entry to palliative care services
Funders 8. Develop collaboration to ensure that funding supports advancement in knowledge, where one study builds from the
finding of another and there is progression to multicentre studies, full evaluations and cost effectiveness studies
9. Assess study proposals against the MORECare statement
National bodies/strategy 10. Develop repositories of routine data and from specific studies which can be used for secondary analysis to quickly
answer current questions
11. Develop collaboration to take forward the MORECare statement
Journal editors/referees 12. In statistical assessment take account of the MORECare statement:
• that attrition due to death and illness is to be expected and should be planned for when designing EoLC studies. It
is not an indication of a poor study unless it is markedly different to that planned, but indicates that a relevant
population of patients and families have been included, giving external validity
• that lack of attrition or missing data is not necessarily a positive finding; it could mean the population studied is less
relevant to EoLC
13. Use MORECare statement to consider good research practice for conducting EoLC studies, alongside established
checklists for reporting, for example, STROBE, CONSORT
EoLC, end of life care; CONSORT, Consolidated Standsrds of Reporting Trials; MORECare, Methods of Researching End of Life Care; STROBE, Strengthening the
Reporting of Observational Studies.
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sensitive [22]. The MORECare project identified vali-
dated outcome measures specifically for palliative care.
Beyond traditional psychometric requirements of face,
content, and construct validity, the MORECare state-
ment includes other requirements for outcome measures
(Table 4). There were, however, strongly opposing views
as to whether the commonly used composite measure of
outcomes, quality-adjusted life years (QALYs), was
appropriate or suitable in EoLC [24]. Debates centred on
whether QALYs should be used in palliative care. Partici-
pants’ questioned the applicability of QALYs as a meas-
ure of outcome for people with life limiting illness and
concern that they fail to demonstrate cost-effectiveness.
Others argued that QALYs were the most widely used
and until alternative measures for palliative care were
available the use of QALYs should continue.
Statistical approaches; handling attrition and missing data
Attrition and missing data are inevitable in EoLC
research. A study which does not have attrition due to
death or worsening illness may justifiably be criticised
for recruiting the wrong patients [21]. We considered
two main approaches to this issue. Firstly, wherever vi-
able, missing data are minimised, using measures which
are as short and simple as possible. Where appropriate,
proxy ratings from carers or staff may fill gaps which
would otherwise exist. Secondly, attrition and missing
data are anticipated. Whilst posing a challenge for statis-
tical analysis, they should not be seen as a fault of the
study design. Instead, the causes of ‘missingness’ require
careful planning for and reporting. We suggest a classifi-
cation of attrition relevant to EoLC studies to describe
causes of attrition (attrition due to death, attrition due
to illness, attrition at random). There may not be a
single correct statistical analysis applicable for all forms
of missing data; however, we suggest an attempt to
model the impact of different forms of imputation to
test the robustness of study conclusions under different
assumptions. These approaches are emergent areas of
methodological development and require further debate
to identify clear solutions. The statistical analysis plan
should include this uncertainty and be prepared and
tested while testing the feasibility of the intervention
(Figure 2).
Discussion
This is the first comprehensive research specifically aimed
at producing evidence-based guidance for researching
treatments and services in EoLC. Our findings propose
using randomised trials and other quasi-experimental or
observational designs, which may be appropriate when
randomisation is not appropriate. Alternative designs
would build on traditional RCT methodology and theMRC framework by integrating observational or natural
experiment methods, and taking account of implementa-
tion aspects, rather than taking a totally different
approach. Mixed methods can be employed at all phases
of development and evaluation. We found that patients
and families value participation in research. Consumer or
patient collaboration in developing studies can be valuable
in ensuring ethical methods and in addressing the con-
cerns of ethics committees. MORECare also concluded
that it is ethically desirable to offer patients and families
the opportunity to take part in research and it may be un-
ethical not to offer this opportunity purely on the grounds
of progressive disease. Outcome measures should be
short, responsive to change and ideally used for both
clinical practice and research. More controversially we
propose that attrition and missing data should be
expected in studies, and does not indicate poor design –
indeed, a lack of attrition may mean that the wrong popu-
lation has been studied. Attrition should be planned for in
advance. A new classification of attrition and missing data
was developed. Implications for implementation need to
be considered at all stages of the project.
MORECare identified the need to involve relevant
methodologists, researchers familiar with the challenges
in EoLC and consumers/patients/families in studies. The
multiple problems of patients mean that interventions
are complex, combining symptom relief and physical,
emotional, social and spiritual care. The teams required
to conduct research in this field, therefore, may also
need to be large and complex. Such teams require man-
agement, and funding bodies may need to take account
of the costs involved.
Our conclusions on the ethical issues raised by EoLC
research challenge earlier thinking, especially that ran-
domisation is unethical [17]. There is growing support
for the need for research into EoLC to improve practice.
The conclusion from the ethics’ TEC was that it can be
unethical not to offer research to this group of individ-
uals. Concerns about approaching patients and families
who are distressed or very ill are understandable, and
this has often led ethics committees or others to raise
concerns regarding research in EoLC. However, the
vulnerability of patients and families is often simplistic-
ally understood. Koffman et al. identified five aspects:
(i) communicative; (ii) institutional; (iii) deferential; (iv)
medical; and (v) social vulnerability, which are relevant
in EoLC and other situations, and might provide a
broader framework for assessment [26].
The new MORECare classification for attrition: ADD –
attrition due to death; ADI attrition due to illness; and
AaR attrition at random – is novel, as is our statement
that attrition should not be seen as an indication of poor
research. Traditionally, guidelines propose that attrition of
5% or lower is inconsequential, whereas 20% or greater is
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line fails to distinguish the reasons for attrition. Data
which are missed because patients have died is very differ-
ent to that missed because a patient has withdrawn con-
sent or because they are symptomatic. To impute data
such as a quality of life score for a patient who has died
seems inappropriate. Whereas imputing data for patients
who have moved away or are missed at random would be
different. Thus, we designed a classification system for
attrition to extend the commonly used classification in
clinical trials of missing completely at random (MCAR),
missing at random (MAR) and missing not at random
(MNAR). We envisage our classification could be used as
an adjunct to understand trial data better. Further, while
attrition introduces potential for bias, our argument is that
a lack of attrition may indicate a different bias, that a less
relevant population has been included. In theory, attrition
can introduce selection bias in randomized trials. Con-
versely, a recent secondary analysis from 10 trials evaluat-
ing treatment of musculoskeletal disorders, challenged
this; the authors found no indication that attrition altered
the results in favour of either treatment or control [28].
Work is needed to explore the effect of attrition on bias in
EoLC studies, and the best ways to impute data. We
believe that our proposed classification will help to clarify
reporting and may well be applicable in other populations
where attrition is high, for example those who are elderly
or frail.
Our findings that outcome measures should be short
and easy to use support and further develop conclusions
from a large European Network on outcome measure-
ment in palliative and EoLC [29]. We propose further
that outcome measurement should be timed to balance
the effect of the intervention and loss of data through
attrition. Tang and McCorkle proposed an alternative
approach, of conducting weekly interviews to ensure
adequate data in end of life care studies [30]. While this
can be appropriate in some circumstances, it may cause
undue interview burden, and we believe the MORECare
recommendation of careful timing is more appropriate.
Our proposal that outcome measures used in research
should also be valuable in clinical practice is novel, as
this is not a usual requirement when assessing outcome
measures, although it relates to aspects in the COSMIN
(COnsensus-based Standards for the selection of health
status Measurement INstruments) checklist of face
validity and responsiveness to change [31]. In EoLC there
are now many different outcome measures. The European
survey identified more than 100 different outcome mea-
sures in palliative care research, but 94 of these were used
fewer than 10 times [32]. There is a need for standardisa-
tion around the few best validated short scales which are
widely used, perhaps with core and add on modules [33],
so that in the future results from studies may be pooled.Policy makers, clinicians and patients responding to
the MORECare consultation raised the need for research
results to be timely to influence service developments.
MORECare concluded that robust evaluation data can
be found beyond RCTs. This is increasingly raised as an
option in research generally [34] and in the most recent
formats of the MRC guidance [11]. Secondary analysis of
existing data sets, including data collected nationally or
in routine clinical practice, and quasi-experimental,
epidemiological and qualitative or especially mixed
methods can be helpful, especially if the original data is
of high quality [34]. Some good examples of secondary
analysis of data are available in the USA, where data on
hospital activity and costs are routinely available [35].
We attempted to identify the key areas of methodo-
logical difficulty in EoLC research; however, we were
limited to conducting only five TECs and three system-
atic reviews, and ideally would have conducted more,
especially regarding more specific recommendations on
recruitment methods, alternatives to the standard RCT
(such as the use of cluster [36] or fast-track trials [37])
and the use of quasi-experimental designs. We see the
MORECare statement as a first step, which ideally will
be expanded and refined through further testing. Argu-
ably we could have conducted a more traditional Delphi
consultation rather than TEC, but the TEC approach
allowed a more interactive discussion by allowing novel
and sometimes challenging proposals. It did limit our
international membership – and only the outcomes
summit (which was conducted alongside an international
congress) had truly international participation. A particu-
lar strength was the involvement of patients and care-
givers in all our TECs and throughout the MORECare
project, which is uncommon in the development of
guidance on good research practice. This involvement
resulted in novel proposals, for example, the recom-
mendation for researchers to attend ethics committee
meetings with patients, caregivers or consumers came
from a patient.
Conclusions
This research study, which integrated data from three sys-
tematic reviews and five TECs, resulted in a statement
(the MORECare Statement) of 36 best practice solutions
for immediate practice and 13 wider recommendations
for national and international consideration. The results
show how ethical research is possible, what is required of
outcome measures, the need for clinical and academic col-
laborations and how mixed method research can be
reported. Some points in the statements challenge current
research practice, for example with new recommendations
regarding anticipating, planning for and managing attri-
tion and missing data. Other points require longer term
change, for example legal change to permit advanced
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on good research practice in evaluating services and treat-
ments in EoLC. The Statement is relevant to those design-
ing, funding and reviewing studies and should be used
alongside existing statements. It provides a first step in
setting common, much needed standards for evaluative
research in EoLC.
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